CCRM
CCRM, a Canadian public-private partnership established with seed funding by the Government of Canada, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of academic researchers, leading companies, strategic investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, funding and infrastructure. CCRM sources and evaluates intellectual property from around the globe, offers various consulting services, conducts development projects with partners, and establishes new companies built around strategic bundles of intellectual property. CCRM has a fully resourced research facility used to both evaluate and advance technologies, a centre for process and analytical development and advanced manufacturing, and a GMP facility within a 40,000 square foot space. In 2022, CCRM established OmniaBio Inc., a commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for cell and gene therapies. CCRM’s model has been adopted outside of Canada in CCRM Australia and CCRM Nordic. CCRM is hosted by the University of Toronto and was launched in Toronto’s Discovery District on June 14, 2011. Visit us at www.ccrm.ca